Pyxis Oncology Stock Short Ratio
| PYXS Stock | USD 2.10 1.72 45.03% |
Pyxis Oncology fundamentals help investors to digest information that contributes to Pyxis Oncology's financial success or failures. It also enables traders to predict the movement of Pyxis Stock. The fundamental analysis module provides a way to measure Pyxis Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pyxis Oncology stock.
Pyxis | Short Ratio |
Pyxis Oncology Company Short Ratio Analysis
Pyxis Oncology's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Pyxis Oncology Short Ratio | 10.78 X |
Most of Pyxis Oncology's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pyxis Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pyxis Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Pyxis Oncology is extremely important. It helps to project a fair market value of Pyxis Stock properly, considering its historical fundamentals such as Short Ratio. Since Pyxis Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pyxis Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pyxis Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Pyxis Oncology has a Short Ratio of 10.78 times. This is 176.41% higher than that of the Biotechnology sector and 45.48% higher than that of the Health Care industry. The short ratio for all United States stocks is 169.5% lower than that of the firm.
Pyxis Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pyxis Oncology's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pyxis Oncology could also be used in its relative valuation, which is a method of valuing Pyxis Oncology by comparing valuation metrics of similar companies.Pyxis Oncology is currently under evaluation in short ratio category among its peers.
Pyxis Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pyxis Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pyxis Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Pyxis Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Pyxis Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pyxis Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pyxis Oncology's value.| Shares | State Street Corp | 2024-06-30 | 742.9 K | Perceptive Advisors Llc | 2024-09-30 | 508.5 K | Boothbay Fund Management, Llc | 2024-06-30 | 492.5 K | Superstring Capital Management Lp | 2024-06-30 | 484.4 K | Northern Trust Corp | 2024-09-30 | 394 K | Hillhouse Capital Advisors, Ltd. | 2024-06-30 | 382.6 K | Decheng Capital Llc | 2024-06-30 | 326.8 K | Bank Of New York Mellon Corp | 2024-06-30 | 311.6 K | Bridgeway Capital Management, Llc | 2024-06-30 | 246.5 K | Deep Track Capital, Lp | 2024-09-30 | 4.2 M | Laurion Capital Management Lp | 2024-06-30 | 3.9 M |
Pyxis Fundamentals
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (3.99) % | ||||
| Current Valuation | 600.03 K | ||||
| Shares Outstanding | 59.47 M | ||||
| Shares Owned By Insiders | 24.54 % | ||||
| Shares Owned By Institutions | 54.50 % | ||||
| Number Of Shares Shorted | 5.86 M | ||||
| Price To Book | 0.81 X | ||||
| Price To Sales | 7.73 X | ||||
| EBITDA | (78.49 M) | ||||
| Net Income | (73.79 M) | ||||
| Cash And Equivalents | 223.36 M | ||||
| Cash Per Share | 7.48 X | ||||
| Total Debt | 21.33 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 15.19 X | ||||
| Book Value Per Share | 2.58 X | ||||
| Cash Flow From Operations | (70.71 M) | ||||
| Short Ratio | 10.78 X | ||||
| Earnings Per Share | (1.06) X | ||||
| Price To Earnings To Growth | 0.01 X | ||||
| Target Price | 10.67 | ||||
| Number Of Employees | 54 | ||||
| Beta | 1.28 | ||||
| Market Capitalization | 124.88 M | ||||
| Total Asset | 173.73 M | ||||
| Retained Earnings | (286.23 M) | ||||
| Working Capital | 98.84 M | ||||
| Net Asset | 173.73 M |
About Pyxis Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pyxis Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pyxis Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pyxis Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.